Search
Now showing items 1-6 of 6
The adenosine A2A antagonistic properties of selected C8-substituted xanthines
(Elsevier, 2013)
The adenosine A2A receptor is considered to be an important target for the development of new therapies
for Parkinson’s disease. Several antagonists of the A2A receptor have entered clinical trials for this purpose
and ...
The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues
(Elsevier, 2015)
Based on a report that sulfanylphthalimides are highly potent monoamine oxidase (MAO) B selective inhibitors, the present study examines the adenosine receptor affinities and MAO-B inhibitory properties of a series of 4- ...
2-Aminopyrimidines as dual adenosine A1/A2A antagonists
(Elsevier, 2015)
In this study thirteen 2-aminopyrimidine derivatives were synthesised and screened as potential antagonists of adenosine A1 and A2A receptors in order to further investigate the structure activity relationships of this ...
Novel sulfanylphthalimide analogues as highly potent inhibitors of monoamine oxidase B
(Elsevier, 2012)
Monoamine oxidase (MAO) plays an essential role in the catabolism of neurotransmitter amines. The two isoforms of this enzyme, MAO-A and -B, are considered to be drug targets for the therapy of depression and neurodegenerative ...
Sulfanylphthalonitrile analogues as selective and potent inhibitors of monoamine oxidase B
(Elsevier, 2012)
It has recently been reported that nitrile containing compounds frequently act as potent monoamine oxidase B (MAO-B) inhibitors. Modelling studies suggest that this high potency inhibition may rely, at least in part, on ...
Benzyloxynitrostyrene analogues: a novel class of selective and highly potent inhibitors of monoamine oxidase B
(Elsevier, 2017)
This study examines a series of novel 3-benzyloxy-β-nitrostyrene analogues as a novel class of inhibitors of the monoamine oxidase (MAO) enzymes. MAO inhibitors are considered useful for the treatment of depression and ...